<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04124055</url>
  </required_header>
  <id_info>
    <org_study_id>S-DBS-TDM-001</org_study_id>
    <nct_id>NCT04124055</nct_id>
  </id_info>
  <brief_title>Saliva and Dried Blood Spot Therapeutic Drug Monitoring for MDR-TB in Tanzania</brief_title>
  <official_title>Saliva and Dried Blood Spot Therapeutic Drug Monitoring for MDR-TB in Tanzania</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jan-Willem C Alffenaar</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>kibong'oto Infectious diseases hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dried blood spot and saliva samples are collected during multidrug resistant tuberculosis&#xD;
      (MDR-TB) treatment to measure the drug concentration of levofloxacin. Feasibility of both&#xD;
      analytical procedures in a high burdened setting is explored.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:&#xD;
&#xD;
      Measuring pharmacokinetic variability of anti-tuberculosis (TB) drugs and responding by dose&#xD;
      correction will allow individualized treatment to improve microbiological response, curb&#xD;
      acquired drug-resistance, protect and extend the efficacy of novel drugs rolled-out to&#xD;
      endemic areas (pharmacovigilance), reduce toxicity to patients and lead to treatment duration&#xD;
      shortening.&#xD;
&#xD;
      Aims and Objectives:&#xD;
&#xD;
      Implement Dried Blood Spot (DBS) collection for performance of high-performance liquid&#xD;
      chromatography (HPLC) to optimize multidrug resistant TB (MDR-TB) treatment in Tanzania.&#xD;
      Simultaneously, provide a proof-of-principle-demonstration that the developed saliva point of&#xD;
      care drug assay for measurement of fluoroquinolone concentration works in a field setting.&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      This will be a phase II prospective diagnostic study among patients from a national referral&#xD;
      of MDR-TB in Tanzania. The investigators anticipate recruiting a minimum of 50 study&#xD;
      participants to power for the primary aim. Subjects will have a minimum amount of blood and&#xD;
      saliva collected for therapeutic drug monitoring and the investigational drug assays&#xD;
      respectively. Expected results include agreement of saliva point-of-care and DBS for&#xD;
      measurement of fluoroquinolone concentrations in HPLC. Other important findings related to&#xD;
      field-testing include the best time for sample collection within the dosing interval and the&#xD;
      algorithmic use of DBS and saliva, and clinical - demographic factors such as HIV&#xD;
      coinfection, concomitant drugs, and diabetes mellitus that may influence the saliva drug&#xD;
      assay results. Performance characteristics (sensitivity, specificity, negative and positive&#xD;
      predictive values) of the saliva point-of care (PoC) and DBS will be calculated as a&#xD;
      measurement of accuracy with reference to the gold standard.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 24, 2019</start_date>
  <completion_date type="Actual">December 31, 2019</completion_date>
  <primary_completion_date type="Actual">December 15, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Drug exposure</measure>
    <time_frame>&gt;2 weeks on treatment</time_frame>
    <description>Drug concentration (mgL)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>MDR-TB</condition>
  <arm_group>
    <arm_group_label>Therapeutic drug monitoring (TDM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Therapeutic drug monitoring (TDM) based on Saliva and Dried blood spot samples</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Therapeutic drug monitoring (TDM)</intervention_name>
    <description>Saliva and dried blood spot samples are collected. Based on the measured drug concentration the dose can be adjusted</description>
    <arm_group_label>Therapeutic drug monitoring (TDM)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant is receiving care at Kibong'oto hospital&#xD;
&#xD;
          -  Age of 18 years or above&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy at any gestation&#xD;
&#xD;
          -  Co-morbid conditions such as generalized severe ulcers, Kaposi sarcoma,&#xD;
&#xD;
          -  Hemophilia&#xD;
&#xD;
          -  Participants with medical conditions like malignancy, dementia or those who will be&#xD;
             critically ill and unable to consent and provide DBS and Saliva.&#xD;
&#xD;
          -  Patients with Karnofsky score less than 40% or moribund&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stellah Mpagama, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kibong'oto ID hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kibong'oto infectious diseases hospital</name>
      <address>
        <city>Kibong'oto</city>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Tanzania</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 9, 2019</study_first_submitted>
  <study_first_submitted_qc>October 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 11, 2019</study_first_posted>
  <last_update_submitted>October 28, 2020</last_update_submitted>
  <last_update_submitted_qc>October 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>Jan-Willem C Alffenaar</investigator_full_name>
    <investigator_title>prof</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis, Multidrug-Resistant</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

